Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.06
$1.37
$1.06
$4.08
$284.36M0.353.45 million shs4.82 million shs
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
$1.26
$1.37
$0.87
$3.19
$76.61M0.21564,850 shs541,860 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.34
$3.14
$1.07
$11.46
$321.61M0.661.38 million shs890,830 shs
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$4.63
$4.88
$2.59
$5.70
$317.11M1.01107,059 shs46,184 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-8.62%-24.56%-12.40%-59.39%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.00%-4.55%-6.67%-34.38%-30.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%+4.05%-3.47%-13.02%-6.44%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
0.00%-10.10%-12.31%-2.32%+56.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.06
$1.37
$1.06
$4.08
$284.36M0.353.45 million shs4.82 million shs
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
$1.26
$1.37
$0.87
$3.19
$76.61M0.21564,850 shs541,860 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.34
$3.14
$1.07
$11.46
$321.61M0.661.38 million shs890,830 shs
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$4.63
$4.88
$2.59
$5.70
$317.11M1.01107,059 shs46,184 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-8.62%-24.56%-12.40%-59.39%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.00%-4.55%-6.67%-34.38%-30.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%+4.05%-3.47%-13.02%-6.44%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
0.00%-10.10%-12.31%-2.32%+56.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.20
Hold$4.67340.25% Upside
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.00
N/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
2.45
Hold$8.75161.98% Upside
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
2.33
Hold$7.5061.99% Upside

Current Analyst Ratings Breakdown

Latest MAIA, SOPH, AKBA, and RZLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Boost Price TargetBuy$4.00 ➝ $10.00
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingSell (E+)
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
DowngradeHoldStrong Sell
5/6/2026
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
Reiterated RatingBuy$8.00
4/21/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Reiterated RatingSell (D-)
4/21/2026
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
Reiterated RatingSell (D-)
4/15/2026
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
Boost Price TargetBuy$7.00 ➝ $8.00
4/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
UpgradeStrong SellHold
4/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingBuy$4.00
3/25/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
UpgradeNeutralOutperform$2.00 ➝ $5.00
3/3/2026
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
Reiterated RatingBuy$7.00
(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M1.20N/AN/A$0.12 per share8.83
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/AN/AN/AN/A$0.06 per shareN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.86 per shareN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$77.27M4.10N/AN/A$0.69 per share6.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
-$22.40M-$1.38N/AN/AN/AN/A-284.80%-142.94%N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%N/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)

Latest MAIA, SOPH, AKBA, and RZLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q3 2026
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.1686-$0.16+$0.0086-$0.16N/AN/A
5/11/2026Q1 2026
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
-$0.18-$0.14+$0.04-$0.14N/AN/A
5/7/2026Q1 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million
5/5/2026Q1 2026
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million
3/23/2026Q4 2025
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
-$0.13-$0.08+$0.05-$0.08N/AN/A
3/3/2026Q4 2025
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.20-$0.28-$0.08-$0.28$21.20 million$21.71 million
2/26/2026Q4 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03-$0.05-$0.02-$0.05$48.37 million$57.62 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.33
1.40
1.33
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/A
5.59
5.59
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
15.84
15.84
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
1.05
2.06
1.90

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
5.65%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
31.59%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
19.81%
Rezolute, Inc. stock logo
RZLT
Rezolute
14.78%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
4.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430268.26 million256.72 millionOptionable
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
960.80 million48.76 millionNot Optionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4096.29 million82.06 millionOptionable
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
52068.49 million65.14 millionNot Optionable

Recent News About These Companies

SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript
SOPHiA GENETICS Q1 Earnings Call Highlights
SOPHiA GENETICS SA
Mount Sinai adopts AI platform to advance genomic testing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$1.06 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$1.09 +0.03 (+2.64%)
As of 05/15/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

MAIA Biotechnology stock logo

MAIA Biotechnology NYSEAMERICAN:MAIA

$1.26 0.00 (0.00%)
Closing price 05/15/2026 04:10 PM Eastern
Extended Trading
$1.29 +0.03 (+2.46%)
As of 05/15/2026 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$3.34 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$3.33 -0.01 (-0.18%)
As of 05/15/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

SOPHiA GENETICS stock logo

SOPHiA GENETICS NASDAQ:SOPH

$4.63 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$4.62 -0.01 (-0.32%)
As of 05/15/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.